Assistant Professor of Physical Medicine and Rehabilitation, School of Medicine
NextGen Focus Area: Inherited Peripheral Neuropathy, Neuromuscular Disorders, Pathomechanism Identification and Candidate Therapeutics
Dr. Moss’ research is focused on identifying cellular and molecular mechanisms driving Charcot-Marie-Tooth disease (CMT) pathogenesis. CMT is one of the most common inherited neurological disorders, yet there are no treatments currently available to patients. Dr. Moss is using advanced mouse and cellular models to dissect CMT pathomechanisms and systems neuroscience to study CMT pathophysiology. Her work aims to identify novel therapeutic targets and strategies for CMT.
Precision Health Impact:
- Advance understanding of CMT pathogenesis
- Identify candidate targets for novel therapeutics
- Contribute to the development of efficacious treatments for CMT patients
Publications:
Hildebrandt RP, Moss KR, Janusz-Kaminska A, Knudson LA, Denes LT, Saxena T, et al. Muscleblind-like proteins use modular domains to localize RNAs by riding kinesins and docking to membranes. Nat Commun. 2023 Jun 9;14(1):3427.
Moss KR, Johnson AE, Bopp TS, Yu AT, Perry K, Chung T, et al. SARM1 knockout does not rescue neuromuscular phenotypes in a Charcot-Marie-Tooth disease Type 1A mouse model. J Peripher Nerv Syst. 2022 Mar;27(1):58–66.
Moss KR, Bopp TS, Johnson AE, Höke A. New evidence for secondary axonal degeneration in demyelinating neuropathies. Neurosci Lett. 2021 Jan 23;744:135595.
Moss KR, Höke A. Targeting the programmed axon degeneration pathway as a potential therapeutic for Charcot-Marie-Tooth disease. Brain Res. 2020 Jan 15;1727:146539.
DeMarco B, Stefanovic S, Williams A, Moss KR, Anderson BR, Bassell GJ, et al. FMRP - G-quadruplex mRNA - miR-125a interactions: Implications for miR-125a mediated translation regulation of PSD-95 mRNA. PLoS One. 2019;14(5):e0217275.
Google Scholar
National Library of Medicine (NCBI)
Email: kmoss@missouri.edu
Department website: https://medicine.missouri.edu/faculty/kathryn-moss-phd